AMD Invests in Drug-Discovery Company Absci in Push to Sell AI Chips The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other ...

--Absci Corporation, a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power ...

Absci’s groundbreaking work in AI drug discovery is a perfect fit for AMD high-performance computing solutions and software, designed for the most demanding AI workloads.” ...

AMD is investing $20 million in AI drug startup Absci, which will use AMD chips and software Last Updated: Jan. 8, 2025 at 9:32 a.m. ET First Published: Jan. 8, 2025 at 8:48 a.m. ET Share ...

Absci partners with AMD, investing $20 million to enhance AI-driven drug discovery and antibody design capabilities. Quiver AI Summary. Absci Corporation has announced a strategic partnership with ...

AMD collaborates with Absci for AI drug discovery advancements. AMD makes a $20 million investment to boost drug research. Get ahead of Wall Street reactions—Benzinga Pro delivers signals ...

Summary. Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI’s main drug candidate for IBD.

VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD ...

VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy ...

$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm SoftwareVANCOUVER, Wash ...

AMD’s support will enable Absci to enhance its proprietary antibody design model, IgDesign1, which is the first in vitro validated inverse folding model for antibody design.